trending Market Intelligence /marketintelligence/en/news-insights/trending/co4ftzpdgatp6g2-taaata2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA grants priority review for Tesaro's cancer drug

Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility

ChangePays Although Still Underrepresented Women in the C Suite are Driving Profitability

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles


Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018

US FDA grants priority review for Tesaro's cancer drug

The U.S. FDA granted a priority review to Tesaro Inc.'s new drug application for niraparib, a poly ADP-ribose polymerase inhibitor.

Niraparib is being evaluated as a potential new treatment option for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer following response to platinum-based chemotherapy.

The application for niraparib is supported by a phase 3 study that showed that niraparib treatment significantly prolonged progression-free survival compared to placebo.

The FDA set a target action date under the Prescription Drug User Fee Act of June 30, 2017, and is not planning to hold an advisory committee meeting to discuss the application.

An expanded access program for niraparib in the U.S. is planned to open in January 2017.